Abnormal uterine bleeding is a complex gynecological problem, especially in the perimenopausal and postmenopausal period. Etiology may be organic (endometrial polyp, hyperplasia, myoma, endometrial atrophy, carcinoma) or non-organic (dysfunctional uterine bleeding).To analyze the histopathological findings of samples of fractionated explorative curettage in patients with abnormal uterine bleeding and to investigate certain risk factors for their occurrence (age, obesity, hypertension, diabetes).This was a prospective study comprising a total of 104 subjects. They were divided into two groups: 54 women in postmenopausal age and 50 in premenopausal age. The data were collected by interviewing and analyzing the findings from histopathological analyses of samples obtained by fractional explorative curettage. The following anamnestic data were analyzed: age, history of hypertension and diabetes. The study was performed in the Special Hospital for Gynecology and Obstetrics "Mother Theresa" -Chair.The most common pathological finding in both groups was endometrial polyp (in 39.5% of postmenopausal and 46.9% of premenopausal women). In 4 participants (5.7% of the total), endometrial adenocarcinoma was diagnosed. The mean age of patients was 57 years in the postmenopausal group and 43 years in the premenopausal group. The average BMI (Body Mass Index) was 33 in the postmenopausal group and 25 in the premenopausal group. Hypertension was detected in 64.8% of postmenopausal women and in 34% of premenopausal women. 13% of postmenopausal women were diagnosed with diabetes. It was detected in 12% of premenopausal women.Fractional explorative curettage is an important diagnostic procedure for prompt and timely diagnosis of premalignant and malignant changes of the female genital tract. We detected endometrial adenocarcinoma in 7,4% of the postmenopausal patients and in 4% of premenopausal patients with abnormal uterine bleeding. It is especially important to highlight obesity and hypertension as risk factors for abnormal uterine bleeding and endometrial pathology.

Placental growth factor (PlGF) is crucial during placental development in early pregnancy. Several studies in pregnancies with complications such as preeclampsia or small for gestational age neonates find that PlGF levels are significantly lower in the first trimester, which implies that the concentration of PlGF could be used as an early screening biomarker for these conditions. This study aimed to compare the performance of chemiluminescence immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) for the quantification of human PlGF in serum. This is a comparative study on 88 pregnant women in the first trimester subjected to measurement of PlGF in serum using two commercially available kits: Human PlGF Quantikine HS ELISA (R&D Systems) and PlGF CLIA (Snibe). The overall coefficient of correlation between the tests was 0.93. When the cut-off value of 40 pg/mL was applied, it dropped significantly to 0.50 towards the lower values, while remaining an excellent 0.91 in the group with higher concentrations of PlGF. While R&D Systems’s ELISA seems to have better sensitivity, it is not very convenient to use for a small number of samples. Snibe’s CLIA automated method is user-friendly, fast and powerful. Both tests show excellent performance when indicating risk-free pregnancies.

No abstract

Objectives: To offer chromosomal microarray in fetuses with structural abnormalities. Methods: A total of 100 subjects was recruited subjected to CMA testing in fetuses with structural abnormalities in a single centre. Results: The number of cardiac anomalies were 18%, thoracic 13%, Renal were 11%, severe onset growth restriction were 10%, CNS abnormalities were 16%, GIT and were 19% and increased Nuchal Translucency were 13%. The proposed CMA test was significant (p < 0.005) and effective, identified chromosomal anomalies with the pick-up rate of the overall 12%. This led to efficient identification of clinically significant sub-chromosomal deletions or duplications, for structurally abnormal pregnancies as diagnosed on USG. Conclusions:This technology open doors for deeper changes in screening policies and recommendations for prenatal care and could be the standard of care for fetuses with structural abnormalities. VP28.16Application of polymerase chain reaction for embryo gender determination using blood of pregnant women